{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:07:29Z","timestamp":1783732049487,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T00:00:00Z","timestamp":1518393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation, Seattle, WA","doi-asserted-by":"publisher","award":["35537"],"award-info":[{"award-number":["35537"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation, Seattle, WA","doi-asserted-by":"publisher","award":["OPP1053353"],"award-info":[{"award-number":["OPP1053353"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.vaccine.2018.02.002","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T23:00:20Z","timestamp":1521586820000},"page":"4816-4822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"PA","title":["Options for design of real-world impact studies of single-dose vaccine schedules"],"prefix":"10.1016","volume":"36","author":[{"given":"Silvia","family":"Franceschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary M.","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Baussano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.vaccine.2018.02.002_b0005","first-page":"118","article-title":"Human papillomavirus vaccines. WHO position paper","volume":"84","author":"World Health Organization","year":"2009","journal-title":"Wkly Epidemiol Rec"},{"issue":"43","key":"10.1016\/j.vaccine.2018.02.002_b0010","first-page":"465","article-title":"Human papillomavirus vaccines: WHO position paper, October 2014","volume":"89","author":"World Health Organization","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.002_b0015","doi-asserted-by":"crossref","first-page":"e0177773","DOI":"10.1371\/journal.pone.0177773","article-title":"Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middle-income countries","volume":"12","author":"Gallagher","year":"2017","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.vaccine.2018.02.002_b0020","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1080\/21645515.2016.1178433","article-title":"The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries","volume":"12","author":"Howard","year":"2016","journal-title":"Human Vaccines Immunother"},{"issue":"7","key":"10.1016\/j.vaccine.2018.02.002_b0025","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S2214-109X(16)30099-7","article-title":"Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis","volume":"4","author":"Bruni","year":"2016","journal-title":"The Lancet Global Health"},{"key":"10.1016\/j.vaccine.2018.02.002_b0030","unstructured":"GAVI. More than 30 million girls to be immunised with HPV vaccines by 2020 with GAVI support. Available at: http:\/\/www.gavi.org\/library\/news\/press-releases\/2012\/more-than-30-million-girls-immunised-with-hpv-by-2020\/ [Accessed on August 17, 2017]."},{"key":"10.1016\/j.vaccine.2018.02.002_b0035","unstructured":"National Cancer Institute. Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines (ClinicalTrials.gov Identifier: NCT03180034). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03180034 [Accessed on August 17, 2012017]."},{"issue":"7","key":"10.1016\/j.vaccine.2018.02.002_b0040","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1470-2045(15)00047-9","article-title":"Efficacy of fewer than three doses of an HPV-16\/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials","volume":"16","author":"Kreimer","year":"2015","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.vaccine.2018.02.002_b0045","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"issue":"10","key":"10.1016\/j.vaccine.2018.02.002_b0050","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/oxfordjournals.aje.a009196","article-title":"Study designs for evaluating different efficacy and effectiveness aspects of vaccines","volume":"146","author":"Halloran","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"7","key":"10.1016\/j.vaccine.2018.02.002_b0055","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/aje\/kwu001","article-title":"Direct, indirect, total, and overall effectiveness of the rotavirus vaccines for the prevention of gastroenteritis hospitalizations in privately insured US children, 2007\u20132010","volume":"179","author":"Panozzo","year":"2014","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.vaccine.2018.02.002_b0060","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2018.02.002_b0065","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/ijc.30092","article-title":"Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda","volume":"139","author":"Franceschi","year":"2016","journal-title":"Int J Cancer"},{"issue":"31","key":"10.1016\/j.vaccine.2018.02.002_b0070","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1016\/j.vaccine.2015.05.078","article-title":"Introduction of a National HPV vaccination program into Bhutan","volume":"33","author":"Dorji","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.02.002_b0075","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12879-016-1539-6","article-title":"Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme","volume":"16","author":"Ngabo","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2018.02.002_b0080","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/ijc.28197","article-title":"Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries","volume":"133","author":"Baussano","year":"2013","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.vaccine.2018.02.002_b0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrclinonc.2015.146","article-title":"HPV-FASTER: broadening the scope for prevention of HPV-related cancer","volume":"13","author":"Bosch","year":"2016","journal-title":"Nature Rev Clin Oncol"},{"issue":"19","key":"10.1016\/j.vaccine.2018.02.002_b0090","first-page":"241","article-title":"Human papillomavirus vaccines: WHO position paper, May 2017","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"issue":"1","key":"10.1016\/j.vaccine.2018.02.002_b0095","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3201\/eid2201.150791","article-title":"Human papillomavirus vaccination at a time of changing sexual behavior","volume":"22","author":"Baussano","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.002_b0100","article-title":"Impact of gender-neutral or girls-only vaccination against human papillomavirus \u2013 Results of a community-randomized clinical trial (I)","author":"Lehtinen","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2018.02.002_b0105","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/1471-2334-14-408","article-title":"Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme","volume":"14","author":"Tshomo","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"9895","key":"10.1016\/j.vaccine.2018.02.002_b0110","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(13)60022-7","article-title":"Human papillomavirus and cervical cancer","volume":"382","author":"Crosbie","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.02.002_b0115","unstructured":"European Commission. European guidelines for quality assurance in cervical cancer screening. Second edition, Supplements. Anttila A, Arbyn A, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J, Ronco G, Segnan N, Suonio E, T\u00f6rnberg S, von Karsa L editors. Office for Official Publications of the European Union, Luxembourg; 2015."},{"issue":"2","key":"10.1016\/j.vaccine.2018.02.002_b0120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/infdis\/jix582","article-title":"Bivalent vaccine effectiveness against type-specific HPV positivity: evidence for cross-protection against oncogenic types among Dutch STI clinic visitors","volume":"217","author":"Woestenberg","year":"2018","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2018.02.002_b0125","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S1473-3099(15)00055-9","article-title":"Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study","volume":"15","author":"Chow","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2018.02.002_b0130","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1158\/1055-9965.EPI-14-0687","article-title":"Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study","volume":"23","author":"Soderlund-Strand","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.vaccine.2018.02.002_b0135","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S2214-109X(14)70354-7","article-title":"Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial","volume":"3","author":"Arrossi","year":"2015","journal-title":"The Lancet Global Health"},{"issue":"7","key":"10.1016\/j.vaccine.2018.02.002_b0140","doi-asserted-by":"crossref","first-page":"e016309","DOI":"10.1136\/bmjopen-2017-016309","article-title":"Cervical cancer screening in rural Bhutan with the careHPV test on self-collected samples: an ongoing cross-sectional, population-based study (REACH-Bhutan)","volume":"7","author":"Baussano","year":"2017","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.vaccine.2018.02.002_b0145","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1086\/421279","article-title":"Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea","volume":"190","author":"Shin","year":"2004","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2018.02.002_b0150","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s10096-014-2147-2","article-title":"Optimization of HPV DNA detection in urine by improving collection, storage, and extraction","volume":"33","author":"Vorsters","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2018.02.002_b0155","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/bjc.2011.30","article-title":"HPV type-specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in Scotland","volume":"104","author":"O'Leary","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2018.02.002_b0160","doi-asserted-by":"crossref","first-page":"g5264","DOI":"10.1136\/bmj.g5264","article-title":"Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis","volume":"349","author":"Pathak","year":"2014","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.vaccine.2018.02.002_b0165","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/1940-6207.CAPR-16-0038","article-title":"Comparison between Urine and Cervical Samples for HPV DNA Detection and Typing in Young Women in Colombia","volume":"9","author":"Combita","year":"2016","journal-title":"Cancer Prevent Res (Philadelphia, Pa)."},{"issue":"1","key":"10.1016\/j.vaccine.2018.02.002_b0170","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12985-017-0744-2","article-title":"Evaluation of the performance of Human Papillomavirus testing in paired urine and clinician-collected cervical samples among women aged over 30 years in Bhutan","volume":"14","author":"Tshomo","year":"2017","journal-title":"Virology J"},{"issue":"9548","key":"10.1016\/j.vaccine.2018.02.002_b0175","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(06)69479-8","article-title":"Sexual behaviour in context: a global perspective","volume":"368","author":"Wellings","year":"2006","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1830166X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1830166X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T01:43:12Z","timestamp":1569375792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1830166X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":35,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0264410X1830166X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.002","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Options for design of real-world impact studies of single-dose vaccine schedules","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}